Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey P.C.M. van de Kerkhof has received honoraria as a speaker and/or consultant, and participated in clinical trials sponsored by AbbVie, Allmirall, Amgen, Celgene, Centocor, Eli Lilly, Galderma, Jansen Cilag, LEO Pharma, Mitsubishi, Novartis, Pfizer, Philips and Sandoz. K. Reich has received honoraria as a speaker and consultant for and participated in clinical trials sponsored by Abbott, Biogen-Idec, Centocor, Janssen-Cilag, Schering-Plough and Wyeth. A. Kavanaugh has served as an investigator for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen and UCB. H. Bachelez has served as a consultant for AbbVie, Almirall, Amgen, Boehringer, Celgene, Centocor, Eli Lilly, Janssen-Cilag, LEO Pharma, MSD, Merck-Serono, Novartis, Pfizer, Sandoz and Takeda. J. Barker has acted as consultant for or spoken at sponsored symposia for or received grant funding from AbbVie, Amgen, Celgene, Centocor, Eli Lilly, Janssen, Merck, Novartis and Pfizer. G. Girolomoni has received honoraria as a speaker and/or consultant by AbbVie, Actelion, Boehringer Ingelheim, Celgene, Dompè, Eli Lilly, Galderma, Janssen, LEO Pharma, Maruho, Merck-Serono, MSD, Mundipharma, Novartis, Otsuka, Pfizer, Rottapharm and Shiseido. R.G. Langley has served as principal investigator for and is on the scientific advisory board of Abbott, Amgen, Centocor and Schering-Plough. C.F. Paul has served as an investigator or consultant for Abbott, Amgen, Astellas, Celgene, Janssen-Cilag, LEO Pharma, Novartis, Pfizer and Pierre Fabre. L. Puig has served as a consultant and/or paid speaker for and/or participated in clinical trials for Abbott, Amgen, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Merck, MSD, Novartis and Pfizer. M.G. Lebwohl has served as an investigator for Amgen, Celgene, Coronado Biosciences, Eli Lilly, Janssen Biotech, LEO Pharma, GlaxoSmithKline and Ranbaxy, and as a consultant for Abbott, Amgen, Anacor, BioLineRx, Celgene, DermiPsor, Eli Lilly, Galderma, Janssen Biotech, LEO Pharma, Maruho Co., Meda, Novartis, Pfizer and Valeant. Available literature on psoriasis and psoriatic arthritis (PsA) demonstrates a tremendous burden of disease and suggests underdiagnosis and undertreatment. To obtain real-world physician perspectives on the impact of psoriasis and PsA and its treatment on patients' daily lives, including perceptions of, and satisfaction with, current therapies. The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) surveyed dermatologists (n = 391) and rheumatologists (n = 390) in North America (Canada and the United States) and Europe (France, Germany, Italy, Spain and United Kingdom).Dermatologists classified 20.3% and 25.7% of their patients as having severe psoriasis and severe PsA respectively; rheumatologists indicated that 48.4% of their PsA patients had active disease. Of the psoriasis patients complaining of joint pain, only 33.0% had a diagnosis of PsA. An impact on daily activities or social/emotional well-